Using an electronic literature search for published articles indexed in PubMed between January 1990 and August 2011, the update of this clinical practice guideline is the result of reviewing 84 clinical trials, 54 reviews, 25 in vitro studies, and 7 evidence-based guidelines. The recommendations below are made following the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) criteria: 1: It is recommended that selection of the appropriate aerosol generator and interface be made based on the patient's age, physical and cognitive ability, cost, and the availability of the prescribed drug for use with a specific device. 2: Nebulizers and pressurized metered-dose inhalers (pMDIs) with valved holding chambers are suggested for use with children < 4 years of age and adults who cannot coordinate the use of pMDI or dry-powder inhaler (DPI). 3: It is suggested that administration of aerosols with DPIs be restricted to patients > 4 years of age who can demonstrate sufficient flow for the specific inhaler. 4: For patients who cannot correctly use a mouthpiece, aerosol masks are suggested as the interface of choice. 5: It is suggested that blow-by not be used for aerosol administration. 6: It is suggested that aerosol therapy be administered with a relaxed and nondistressed breathing pattern. 7: Unit dose medications are suggested to reduce the risk of infection. 8: It is suggested that nebulizer/drug combinations should be used as approved by the FDA. 9: It is recommended that healthcare providers know the correct use of aerosol generators; they should teach and periodically re-teach patients about how to use aerosol devices correctly. 10: It is suggested that intermittent positive-pressure breathing should not be used for aerosol therapy. 11: It is recommended that either nebulizer or pMDI can be used for aerosol delivery during noninvasive ventilation.
ery into the eyes, to optimize inhaled dose. 18 -24 Aerosol generators are equally efficacious if they are age appropriate and used correctly. [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] Regardless of age, patients need to demonstrate ability to seal the lips around the mouthpiece and ability to generate sufficient flow for the specific inhaler. Table 1 provides age guidelines for use of aerosol delivery device types.
This clinical practice guideline (CPG) addresses the selection of an aerosol delivery device for the administration of inhaled medications by small-volume nebulizer (SVN), large-volume nebulizer (LVN), pressurized metered-dose inhaler (pMDI), and dry-powder inhaler (DPI) to spontaneously breathing patients without an artificial airway. Studies on spontaneously breathing patients with tracheostomy were excluded from this CPG, due to lack of evidence in this area of research. Using an electronic literature search for published articles indexed in PubMed between January 1990 and August 2011, the update of this CPG is result of reviewing 84 clinical trials, 54 reviews, 25 in vitro studies, and 7 evidence-based guidelines. The search terms used in this CPG include nebulizer, dry-powder inhaler, metered-dose inhaler, aerosol, face mask, mouthpiece, hood, blow-by, valved holding chamber (VHC), spacer, patient education, patient adherence, noninvasive ventilation, and device selection.
1.1 Small-Volume Nebulizer. SVNs are divided into 3 types: jet nebulizer, mesh nebulizer, and ultrasonic nebulizer. The jet nebulizer is powered by a compressed gas source, in the form of a compressor or hospital pressurized gas source such as piped medical gas or high pressure tanks. The medication is displaced up a capillary tube from the nebulizer's reservoir and is dispersed continuously as aerosolized particles. 14,40 -43 There are 4 types of jet nebulizer: jet nebulizer with reservoir tube, jet nebulizer with collection bag, breath-actuated jet nebulizer, and breathenhanced jet nebulizer. Jet nebulizer with reservoir tube is the most commonly used and generates continuous aerosol during the entire breathing cycle. Jet nebulizer with a reservoir bag collects aerosol leaving the jet nebulizer when patient is not inhaling. Thus, it increases dose efficiency by delivering aerosol in the reservoir bag with the next inspiration. While the breath-actuated jet nebulizer generates aerosol only during inspiration, which reduces loss of medication during expiration, the breath-enhanced jet nebulizer uses one-way valves to prevent the loss of aerosol to the environment and to increase aerosol delivery to the patient. Mesh nebulizer is powered by electricity to create aerosol by way of an aperture plate or an ultrasonic horn. The diameter of the mesh or aperture determines the size of the particle generated. 14,44 -46 Ultrasonic nebulizer is also powered by electricity to create high frequency vibrations in a piezo crystal, which are transferred to the surface of the solution, creating a standing wave that generates aerosol. 14 The aerosolized particles are inhaled by the patient or delivered in conjunction with positive-pressure breaths such as intermittent positive-pressure breathing, noninvasive ventilation (NIV), and intrapulmonary percussive ventilation. Whereas aerosol delivery via SVN with intermittent positive-pressure breathing is less efficient than SVN alone, 47 using NIV for aerosol therapy is feasible and effective in improving bronchospasm. 48 -52 However, it should be noted that aerosol delivery with NIV is influenced by the NIV settings, the leak port position, the type of aerosol generator, and the interface used during the treatment. [53] [54] [55] For instance, increasing the inspiratory pressure during NIV increases aerosol deposition, as opposed to increased expiratory pressure, which decreases aerosol delivery. 53 The efficiency of an aerosol generator is influenced by the location of the leak port. If the leak port is distal to the device, drug delivery is greater than at the proximal location, regardless of the type of aerosol generator used. 54,55 Consequently, drug delivery via mask with a leak port is less than that without. If the leak port is in the mask, the efficiency of pMDI is better than that of nebulizer because aerosol loss with pMDI during expiration is less, compared to the nebulizer. According to a recent in vitro comparison, aerosol deposition with mesh nebulizer is significantly greater, compared to the jet nebulizer during NIV. 55 Also, the use of nebulization with NIV is better than nebulization alone in some patients. 52 The intrapulmonary percussive ventilator is primarily an airway clearance device, but it is usually combined with a nebulizer, although its physiologic and clinical effects have not been studied extensively. Studies have shown that aerosol deposition with the intrapulmonary percussive ventilator is significantly lower than with a standard nebulizer alone and has large inter-individual variability. 56, 57 
ADS 3.0 PROCEDURE
It is recommended that techniques for using aerosol delivery devices follow the procedural steps from A Guide to Aerosol Delivery Devices for Respiratory Therapists. 14 In some cases, the FDA has approved a drug-device combination with specific nebulizers identified on the drug label. Table 2 shows approved nebulizers for specific drug formulations. 14 The use of specified nebulizers is recommended. 134 Since filling volumes may be different, it is suggested to follow the drug label or device manufacturer's product insert to cover those devices that are not labeled for specific use with a particular medication. 10.1.6 Approximately 25-50% of the initial solution volume remains on the internal walls and reservoir of the jet nebulizer after aerosol therapy is completed. 41 Table 3 shows the cost of nebulizers.
ADS 4.0 FOLLOW-UP CARE

11.1.5.2
Since aerosol treatment with pMDI reduces the treatment time at the bedside and increases the productivity of respiratory therapists, it is considered an economical alternative to nebulizer for aerosol delivery to patients with pulmonary diseases. 140,141,159 -164 Previous studies reported success in substituting a pMDI for a nebulizer by documenting a 30 -50% reduction in the annual cost of aerosol therapy. 140, 142, 165, 166 However, success in this substitution depends on proper planning, careful implementation, and comprehensive education programs that were directed to physicians, respiratory therapists, and other healthcare professionals. Also, it must be noted that some medications are not available in the form of pMDI, and some patients are not capable of using pMDI correctly, due to their age and physical and cognitive abilities. 11.2 Most healthcare providers do not know how to use aerosol generators correctly. 167 157 Hyperventilation should be avoided, and the patient should be observed to ensure that aerosol mist is being inhaled. 12.1.2 pMDI actuation occurs at the beginning of inhalation, followed by a slow inspiration and breath-hold for up to 10 seconds. 157 
12.1.3
Patient is able to produce a rapid inhalation in order to fully activate and discharge DPI. 
